DRUG-METABOLIZING-ENZYMES RELATED TO LABORATORY MEDICINE - CYTOCHROMES P-450 AND UDP-GLUCURONOSYLTRANSFERASES

被引:24
作者
BATT, AM
MAGDALOU, J
VINCENTVIRY, M
OUZZINE, M
FOURNELGIGLEUX, S
GALTEAU, MM
SIEST, G
机构
[1] CTR MED,CNRS,URA 597,F-54000 NANCY,FRANCE
[2] CTR MED PREVENT,F-54501 VANDOEUVRE NANCY,FRANCE
关键词
CYTOCHROMES P-450; UDP-GLUCURONOSYLTRANSFERASES; PHENOTYPES; GENOTYPES;
D O I
10.1016/0009-8981(94)90214-3
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Many studies on drug metabolism have been carried out during the last decades using protein purification, molecular cloning techniques and analysis of polymorphisms at phenotype and genotype levels. These researches led to a better understanding of the role of drug metabolizing enzymes in the biotransformation of drugs, pollutants or foreign compounds and of their use in laboratory medicine. The metabolic processes commonly involved in the biotransformation of xenobiotics have been classified into functionalization reaction (phase I reactions), which implicate lipophilic compounds. These molecules are modified via monooxygenation, dealkylation, reduction, aromatization, hydrolysis and can be substrates for the phase II reactions, often called conjugation reactions as they conjugate a functional group with a polar, endogenous compound. This review, devoted to cytochromes P-450 (CYP) and UDP-glucuronosyltransferases (UGT), describes essentially the genetic polymorphisms found in humans, their clinical consequences and the methods to assess the phenotypes or genotypes, with a view to studying the interindividual differences in drug monooxygenation and drug glucuronidation. Variations in drug glucuronidation reported here focused essentially on variations due to physiological factors, induction, drug interactions and genetic factors in disorders such as Gilbert's Syndrome and Crigler-Najjar type I and II diseases.
引用
收藏
页码:171 / 190
页数:20
相关论文
共 111 条
  • [1] METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER
    AYESH, R
    IDLE, JR
    RITCHIE, JC
    CROTHERS, MJ
    HETZEL, MR
    [J]. NATURE, 1984, 312 (5990) : 169 - 170
  • [2] ALTERED DISTRIBUTION OF DEBRISOQUINE OXIDATION PHENOTYPES IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS
    BAER, AN
    MCALLISTER, CB
    WILKINSON, GR
    WOOSLEY, RL
    PINCUS, T
    [J]. ARTHRITIS AND RHEUMATISM, 1986, 29 (07): : 843 - 850
  • [3] BARBEAU A, 1985, LANCET, V2, P1213
  • [4] ENZYME-INDUCTION BY DRUGS AND TOXINS
    BATT, AM
    SIEST, G
    MAGDALOU, J
    GALTEAU, MM
    [J]. CLINICA CHIMICA ACTA, 1992, 209 (1-2) : 109 - 121
  • [5] HUMAN ANTI-ENDOPLASMIC RETICULUM AUTOANTIBODIES APPEARING IN A DRUG-INDUCED HEPATITIS ARE DIRECTED AGAINST A HUMAN-LIVER CYTOCHROME-P-450 THAT HYDROXYLATES THE DRUG
    BEAUNE, P
    DANSETTE, PM
    MANSUY, D
    KIFFEL, L
    FINCK, M
    AMAR, C
    LEROUX, JP
    HOMBERG, JC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (02) : 551 - 555
  • [6] OXIDATIVE POLYMORPHISM OF DEBRISOQUINE IN PARKINSONS-DISEASE
    BENITEZ, J
    LADERO, JM
    JIMENEZJIMENEZ, FJ
    MARTINEZ, C
    PUERTO, AM
    VALDIVIELSO, MJ
    LLERENA, A
    COBALEDA, J
    MUNOZ, JJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (04) : 289 - 292
  • [7] POLYMORPHIC OXIDATION OF DEBRISOQUINE IN LUNG-CANCER PATIENTS
    BENITEZ, J
    LADERO, JM
    JARA, C
    CARRILLO, JA
    COBALEDA, J
    LLERENA, A
    VARGAS, E
    MUNOZ, JJ
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (02) : 158 - 161
  • [8] MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE
    BERTILSSON, L
    DAHL, ML
    SJOQVIST, F
    ABERGWISTEDT, A
    HUMBLE, M
    JOHANSSON, I
    LUNDQVIST, E
    INGELMANSUNDBERG, M
    [J]. LANCET, 1993, 341 (8836) : 63 - 63
  • [9] PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN
    BERTILSSON, L
    LOU, YQ
    DU, YL
    LIU, Y
    KUANG, TY
    LIAO, XM
    WANG, KY
    REVIRIEGO, J
    ISELIUS, L
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 388 - 397
  • [10] HEPATIC BILIRUBIN UDP-GLUCURONYL TRANSFERASE ACTIVITY IN LIVER DISEASE AND GILBERTS SYNDROME
    BLACK, M
    BILLING, BH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1969, 280 (23) : 1266 - &